Search results
Added:
1 year ago
Added:
3 years ago
Atherosclerosis is a systemic disease that can silently affect the entire vascular system and often manifests clinically as stroke, myocardial infarction or sudden cardiac death. Despite advances in diagnosis and treatment, the sequelae of atherosclerosis remain the leading cause of death in adult Americans. Traditionally the gold standard for the diagnosis and assessment of atherosclerosis…
View more
Added:
2 years ago
Added:
3 years ago
Atherosclerosis and its thrombotic complications are the first cause of mortality and morbidity in industrialized countries. Furthermore, despite pharmacological intervention and lifestyle changes, cardiovascular disease (CVD) continues to be the principal cause of death in the US. Despite great advances in the understanding of the initiation and progression of atherosclerosis and its risk…
View more
Added:
3 years ago
Atherosclerosis and its thrombotic complications are the first cause of mortality and morbidity in industrialized countries. Furthermore, despite pharmacological intervention and lifestyle changes, cardiovascular disease (CVD) continues to be the principal cause of death in the US.1 Despite great advances in the understanding of the initiation and progression of atherosclerosis and its risk…
View more
Added:
3 years ago
Most cases of myocardial infarction and stroke occur when a thrombus is formed on a previously stable plaque that ruptures.1 Persons at risk typically have no premonitory symptoms, and angiographic studies of coronary arteries in patients with non-fatal acute coronary syndromes (ACS) showed that most such events are due to rapid progression of mild, hemodynamically insignificant lesions.2–4…
View more
Added:
3 years ago
Sudden cardiac death (SCD) remains a public health problem of immense magnitude, afflicting an estimated 300,000 persons per year in the US.1 SCD, defined as death occurring within one hour from symptom-onset, is associated with ischemic heart disease in 80% of cases. Approximately one-third of cases are the result of an acute occlusion of an epicardial coronary artery.2 Some 50% of the mortality…
View more
Added:
2 months ago
Added:
2 years ago
In this late-breaking interview focusing on the PACMAN-AMI Trial, Prof Lorenz Räber (Bern University Hospital, CH) reveals that the use of alirocumab reduced coronary plaque regression in patients with acute myocardial infarction (AMI) (NCT03067844).
Originally presented by Prof Raber at ACC.22, these findings suggest that alirocumab, on top of high-intensity statin therapy, may be an effective…
View more
Added:
1 year ago
ACC.23/WCC — Principle investigator of YELLOW III, Dr Annapoorna Subhash Kini(Mount Sinai Hospital, US) joins us to talk about the study that assessed the effect of evolocumab (Repatha) on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in 140 patients with stable CAD on maximally tolerated statin therapy …
View more
